IDEAYA Biosciences (IDYA) Non-Current Deffered Revenue (2018 - 2025)

IDEAYA Biosciences has disclosed Non-Current Deffered Revenue across 5 years of filings, most recently posting $1.7 million for Q3 2025.

• Non-Current Deffered Revenue for Q3 2025 came in at $1.7 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $1.7 million (changed N/A YoY), and the FY2022 annual result was $5.2 million, down 83.38% from the prior year.
• Non-Current Deffered Revenue came in at $1.7 million for Q3 2025 at IDEAYA Biosciences, down from $5.2 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $52.1 million in Q1 2021 to a low of $1.7 million in Q3 2025.
• The 3-year median for Non-Current Deffered Revenue is $10.2 million (2022), against an average of $22.5 million.
• Across the five-year window, Non-Current Deffered Revenue decreased 15.02% in 2021 and sank 83.38% in 2022, its largest moves.
• IDEAYA Biosciences' Non-Current Deffered Revenue stood at $31.2 million in 2021, then tumbled by 83.38% to $5.2 million in 2022, then slumped by 67.68% to $1.7 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $1.7 million (Q3 2025), $5.2 million (Q4 2022), and $7.3 million (Q3 2022), per Business Quant data.